Clinical Investigation to Assess a New Artificial Urinary Sphincter to Treat Urinary Incontinence in Men (SOPHIA)

UroMems

Status: Active, not recruiting

Conditions: Urinary Incontinence,Stress

Treatments: Device: UroMems artificial urinary sphincter

Study type: Interventional

Funder types: Industry

Identifiers

NCT05547672

CIP CSO2012031234

Details and patient eligibility

About

Prospective multicenter study designed to test the feasibility of the UroMems Artificial Urinary Sphincter.

Full description

This study is a prospective, open-label, non-randomized, multi-center, single-arm, study with subjects acting as their own control designed to test the feasibility of a new artificial urinary sphincter the UroMems eAUS (investigational name of device called UroActive).

Enrollment: 6 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged >18 years old
• Male patient
• Cognitively able and willing to sign an informed consent
• Stable medication regimen (including prescription, over the counter, and supplements) for the past 3 months
• Able and willing to comply with follow-up investigations, including maintaining consistent medication use and fluid intake through the primary endpoints
• Has adequate cognitive and manual capabilities to operate the UroMems eAUS System as assessed by the investigator
• Is an appropriate surgical candidate and has no medical or mental condition that would interfere with study procedures or confound study outcomes as assessed by the investigator
• Life expectancy ≥ 5 years as assessed by the investigator
• Affiliated with an appropriate social security system
• Has failed or is not a candidate for other treatments for urinary incontinence, either surgical or conservative, including slings, Pro-ACT, etc. (excluding other AUS devices)
• Negative urine culture prior to the procedure
• Urinary incontinence assessed by investigator with at least ≥ 50 g in 24-hour pad-weight tests
• Clinically insignificant post-void residual (PVR) urine defined as < 50 ml and/or no greater than 10% of the voided volume
• Complains of urine leakage on coughing, laughing, and/or moving and/or presence of orthostatic urine leakage by self-report as recorded in baseline bladder diary

Exclusion criteria

• Currently enrolled or plans to enroll in another investigational device or clinical drug trial or has completed an investigational study within 3 months
• Vulnerable patient (patient deprived of their liberty due to a judicial or administrative decision, patient suffering from psychiatry troubles preventing him from giving his consent, patients hospitalized for reason other than the current clinical investigation, patient under 18 years of age, patient under tutelage, patient having withdrawn his consent)
• Patients whom the investigator determines to be poor candidate for surgical procedures and/or anesthesia due to physical or mental conditions
• Patient presenting one or several contraindications of the device
• Any planned procedure requiring urethral catheterization 12 months after implant procedure (include intermittent catheterization) except for diagnostic purposes
• Known allergy to UroMems eAUS implantable components
• Known allergy to intravenous iodine
• Abnormal Prostate Screening Antigen (PSA), according to site's laboratory standards, unless further investigation confirms the absence of primary prostate cancer or local recurrence assessed by investigator.
• Uncontrolled diabetes mellitus defined as persistent blood sugar level recordings of >12 mmol/l (216 mg/dl) and a glycosylated hemoglobin (HbA1C) of >9% (75 mmol/mol) over the preceding 3 months
• History of bleeding diathesis or cannot stop usage of an anti-coagulant until the International Normalized Ratio (INR) is below 1.5 or quick value >70
• Any genito-urinary malignancies which are not in remission for at least 2 years or considered cured, except prostate cancer
• Previous AUS implant
• Currently has another Active Implantable Medical Device (AIMD) implanted
• Urge incontinence, mixed incontinence (MI) with a predominant urgency component
• Overflow urinary incontinence
• Neurogenic bladder dysfunction that is not treatable or controllable by pharmacological or any alternative methods
• Abnormal or poor bladder compliance defined as being <30 ml/ cm H2O
• Bladder neck or urethral stricture that may require any long-term instrumental treatment

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

6 participants in 1 patient group

UroMems artificial urinary sphincter

Experimental group

Description:

Male adults (18+) with urinary incontinence with reduced outlet resistance due to intrinsic sphincter deficiency. Intervention: device (UroMems artificial urinary sphincter)

Treatment:

Device: UroMems artificial urinary sphincter